| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.4M | — | -77.6% |
| R&D Expense | $26.6M | — | +2.2% |
| SG&A Expense | $6.8M | — | -32.2% |
| Operating Income | -$31.9M | — | -7.8% |
| Pre-tax Income | -$31.0M | — | -1.7% |
| Income Tax | $0 | — | -100.0% |
| Net Income | -$31.0M | — | -1.3% |
| EPS (Basic) | -$0.08 | — | +42.9% |
| EPS (Diluted) | -$0.08 | — | +42.9% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $27.6M | +31.7% | +9.6% |
| Accounts Receivable | $873K | +135.3% | +138.5% |
| Current Assets | $37.1M | +3.6% | -1.3% |
| Total Assets | $60.0M | +0.4% | -30.4% |
| Current Liabilities | $53.1M | +25.1% | +7.2% |
| Total Liabilities | $78.9M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$19.3M | — | +26.3% |
| Capital Expenditures | $13K | — | — |
| Investing Cash Flow | -$13K | — | — |
| Financing Cash Flow | $26.7M | — | +228.2% |
| Free Cash Flow | -$19.3M | — | +26.2% |
| -2.9% |
| Stockholders' Equity | -$19.0M | -32.8% | -486.4% |